This clinical trial studies donor peripheral blood stem cell or bone marrow transplant in treating patients with lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation (TBI) before a donor peripheral blood stem cell (PBSC) or bone marrow transplant (BMT) helps stop the growth of cancer cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00612716.
OBJECTIVES:
I. Can allogeneic transplantation using unrelated or partially matched allogeneic marrow or cord blood donors result in timely, complete and durable engraftment in recipients with advanced lymphoproliferative malignancies?
II. What is the incidence and grade of acute and of chronic graft-vs-host disease (GVHD) observed following such allogeneic transplant?
III. Can the augmented graft versus tumor effect accompanying unrelated or partially matched donor allogeneic transplant reduce the incidence of relapse for these high risk malignancies?
OUTLINE:
PREPARATIVE REGIMEN: Patients receive cyclophosphamide intravenously (IV) over 2 hours on days -7 and -6 and undergo TBI* on days -4 to -1.
NOTE: *Patients not eligible to undergo TBI receive busulfan orally (PO) or IV every 6 hours on days -9 to -6 and cyclophosphamide IV over 2 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic PBSC transplant (PBSCT) or BMT on day 0.
Lead OrganizationUniversity of Minnesota/Masonic Cancer Center
Principal InvestigatorDaniel Jordan Weisdorf
